UK markets closed

GSK Jan 2023 41.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
As of 02:34PM EST. Market open.
Full screen
Previous close0.1500
Open0.1500
Bid0.0000
Ask0.7500
Strike41.00
Expiry date2023-01-20
Day's range0.1500 - 0.1500
Contract rangeN/A
Volume295
Open interestN/A
  • Fool.co.uk

    3 reasons why GSK’s share price is a brilliant bargain!

    I'm looking for the best FTSE 100 value stocks to buy in December. And I think the sinking GSK share price provides an excellent investing opportunity. The post 3 reasons why GSK’s share price is a brilliant bargain! appeared first on The Motley Fool UK.

  • Reuters

    GSK to stop selling blood cancer drug Blenrep in United States

    (Reuters) -GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business. The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA). On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients would have the option to enrol for continued access to the treatment.

  • Zacks

    Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

    Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.